


Figures

Figure 7 (Analysis 2.1)




Risk of bias legend

- (A) Sequence Generation
- (B) Allocation concealment
- (C) Blinding of participants and personnel
- (D) Blinding of outcome assessors
- (E) Incomplete outcome data
- (F) Selective outcome reporting
- (G) Other sources of bias

Forest plot of comparison: 2 Alitretinoin vs placebo, by disease category, outcome: 2.1 10mg: Sværhedsgrad af eksemet, længste follow up (PGA clear/almost clear).

Figure 8 (Analysis 2.2)




Risk of bias legend

- (A) Sequence Generation
- (B) Allocation concealment
- (C) Blinding of participants and personnel
- (D) Blinding of outcome assessors
- (E) Incomplete outcome data
- (F) Selective outcome reporting
- (G) Other sources of bias

Forest plot of comparison: 2 Alitretinoin vs placebo, by disease category, outcome: 2.2 20mg: Sværhedsgrad af eksemet, længste follow up (PGA clear/almost clear).

Figure 9 (Analysis 2.3)




Risk of bias legend

- (A) Sequence Generation
 (B) Allocation concealment
 (C) Blinding of participants and personnel
 (D) Blinding of outcome assessors
 (E) Incomplete outcome data
 (F) Selective outcome reporting
 (G) Other sources of bias

Forest plot of comparison: 2 Alitretinoin vs placebo, by disease category, outcome: 2.3 30mg: Sværhedsgrad af eksemet, længste follow up (PGA clear/almost clear).

Figure 11 (Analysis 2.4)



Risk of bias legend

- (A) Sequence Generation
 (B) Allocation concealment
 (C) Blinding of participants and personnel
 (D) Blinding of outcome assessors
 (E) Incomplete outcome data
 (F) Selective outcome reporting
 (G) Other sources of bias

Forest plot of comparison: 2 Alitretinoin vs placebo, by disease category, outcome: 2.4 40mg: Sværhedsgrad af eksemet, længste follow up (PGA clear/almost clear).